What is Kalypsys?
Kalypsys operates at the forefront of pharmaceutical innovation, integrating capabilities in drug discovery, medicinal chemistry, and translational medicine with proprietary automated technologies. This synergistic approach enables the company to discover and develop high-quality, small molecule drugs with enhanced speed and efficiency. The company's pipeline targets critical therapeutic areas, aiming to address unmet medical needs in oncology, cardiovascular/metabolic diseases, and pain/inflammation. Beyond its internal development efforts, Kalypsys collaborates with leading pharmaceutical entities to accelerate the advancement of their next-generation medicines.
How much funding has Kalypsys raised?
Kalypsys has raised a total of $172M across 3 funding rounds:
Series A
$43M
Series B
$29M
Series C
$100M
Series A (2002): $43M with participation from Lombard Odier & Cie, Aravis Ventures, and Novartis Venture Fund
Series B (2004): $29M led by Novartis Venture Fund
Series C (2006): $100M supported by KT Venture Group
Key Investors in Kalypsys
Novartis Venture Fund
Novartis Venture Fund is the venture capital arm of Novartis, a global pharmaceutical giant. They specialize in investing in early-stage companies with innovative technologies and therapies, particularly in areas aligned with Novartis's research and development focus, such as oncology and metabolic diseases.
Aravis Ventures
Aravis Ventures is a private equity firm based in Switzerland that focuses on high-tech growth investments. Their expertise often lies in supporting biotech and life sciences companies, providing both capital and strategic guidance to scale their operations and advance their product pipelines.
KT Venture Group
KT Venture Group is the investment arm of KLA-Tencor, a leader in process control and yield management solutions for the semiconductor industry. While their primary focus is in semiconductor technology, their investment in Kalypsys suggests an interest in companies leveraging advanced technology for drug development or related fields.
What's next for Kalypsys?
The recent major strategic investment signals a pivotal phase for Kalypsys, likely enabling the company to accelerate its clinical development programs and potentially expand its research and development initiatives. This infusion of capital is expected to bolster its efforts in bringing novel therapies to market, particularly in its focus areas of oncology and metabolic diseases. The company's established approach, combining advanced technology with scientific expertise, positions it for continued growth and impact in the pharmaceutical landscape.
See full Kalypsys company page
